REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia
MOTIV BTK randomized trial met primary efficacy endpoint, with early and sustained clinical benefit in a complex patient population SAN DIEGO, April 21, 2026 /PRNewswire/ — REVA Medical, LLC today announced primary
